Chief Executive Officer and Director · Tvardi Therapeutics, Inc. (CARA)

Imran Alibhai

A named executive officer of Tvardi Therapeutics in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$3,116,090

Salary $620,000

FY2024: $857,330

1st of 6 named executive officers at Tvardi Therapeutics by FY2025 total.

6 named officers on file for Tvardi Therapeutics, FY2025

Imran Alibhai’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Tvardi Therapeutics’s whole pay program stands against its peers

  • Tvardi Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CARA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 23, 2026 (DEF 14A).

Free

Get Imran Alibhai’s full pay file as a PDF — free

More than this page: up to 10 years of Imran’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Imran Alibhai compensation by year

Tvardi Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Tvardi Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$551,050$620,000
Bonus$275,525—
Option awards—$2,173,903
Non-equity incentive—$289,850
All other$30,755$32,337
Total$857,330$3,116,090

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Tvardi Therapeutics, Inc. DEF 14A filed April 23, 2026, accession 0001104659-26-047695, and prior-year filings.

How this page was built: the Tvardi Therapeutics, Inc. filed document, accession 0001104659-26-047695. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2026.

$857K
$3.1M
FY24
FY25
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option182,320—$17.04
Option47,500—$4.20

Per the Outstanding Equity Awards at Fiscal Year-End table in Tvardi Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Tvardi Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Imran Alibhai · this pageChief Executive Officer and Director$3,116,090
Christopher PosnerFormer (Cara) President and Chief Executive Officer$2,570,260
John KauhChief Medical Officer$1,156,652
Dan ConnChief Financial Officer$1,139,451
Ryan MaynardFormer (Cara) Chief Financial Officer$1,131,912
Scott TerrillionFormer (Cara) General Counsel, Secretary and Chief Compliance Officer$1,112,438

Board service

Tvardi Therapeutics board · FY2025

How this board is paid

Company policy: Tvardi Therapeutics pays directors a $40,000 cash retainer. As stated in Tvardi Therapeutics's FY2025 proxy.

The full Tvardi Therapeutics compensation record

free company brief

This page is one person within Tvardi Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Tvardi Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Imran Alibhai's compensation dossier · One-time report. No refunds.